Anaerobutyricum hallii was isolated from human faeces.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
Product Information | |
---|---|
Product Overview | Anaerobutyricum hallii was isolated from human faeces. |
Target | Anaerobutyricum |
Genus | Anaerobutyricum |
Strain Designation | VPI B4-27 |
Application | Study and research |
Type Strain | Yes |
Culture Medium | Medium 110 |
Culture Conditions | 37°C; Anaerobic |
Source | Human faeces |
Risk Group | 1 |
Genbank Accession Numbers | Whole genome shotgun sequence: ACEP00000000 |
Product Format | Freeze-dried |
Packaging | Ampoule tube |
Storage | -80°C |
Shelf Life | 6 years |
Target Introduction | |
---|---|
Introduction | Anaerobutyricum is an anaerobic bacterial genus that lives inside the human digestive system. |
Alternative Names | Anaerobutyricum hallii |
Anaerobutyricum hallii should be stored in an anaerobic environment at -80°C to preserve its viability and functionality. It is critical to avoid repeated freeze-thaw cycles, which can significantly diminish the bacterial activity and integrity.
For optimal experimental outcomes, an inoculum size of approximately 1 × 10^6 CFU/mL is recommended. This concentration ensures robust growth and metabolic activity, suitable for various research applications.
Anaerobutyricum hallii is best cultured in YCFA (Yeast extract, Casitone, Fatty Acid) medium, supplemented with glucose, lactate, and glycerol. This medium supports its growth and metabolic processes, including the production of short-chain fatty acids such as butyrate and propionate.
Under optimal anaerobic conditions at 37°C, Anaerobutyricum hallii typically reaches log phase growth within 12-18 hours. Monitoring the growth curve is essential for determining the precise time to harvest the cells for downstream applications.
Preparation for in vivo studies involves growing the culture to the desired phase, harvesting the cells via centrifugation, and resuspending them in a suitable carrier, such as glycerol or phosphate-buffered saline (PBS). This preparation ensures accurate dosing and consistency in experimental applications.
Impact of supplementing microbiomes with A. hallii on PhIP transformation, glycerol metabolism, and SCFAs in batch-fermented fecal microbiota
The research focused on the role of Anaerobutyricum hallii in the transformation of the dietary carcinogen PhIP in diverse human fecal microbiota. Utilizing shotgun metagenomics, the study analyzed the taxonomic profiles and the abundance of glycerol/diol dehydratase (gdh)-harboring taxa in fecal samples from 20 healthy adults. The results revealed that A. hallii was the dominant gdh-harboring taxon in 18 of the 20 samples, contributing significantly to PhIP transformation. Fecal microbiota with a high abundance of A. hallii transformed more PhIP than those with low abundance. Supplementing microbiota with A. hallii further increased PhIP transformation capacity, demonstrating its potential in reducing carcinogen exposure.
Experimentally, supplementing fecal microbiota with A. hallii increased PhIP transformation from 0% to 4% after 6 hours in microbiota with initially low A. hallii levels. This enhancement in PhIP transformation capacity was associated with an increased production of acrolein, a reactive metabolite. The findings suggest that A. hallii supplementation could be a viable strategy for mitigating the mutagenic effects of dietary carcinogens, emphasizing its significance in promoting gut health and reducing cancer risk.
Ramirez Garcia, A., Greppi, A., et al. Anaerobutyricum hallii promotes the functional depletion of a food carcinogen in diverse healthy fecal microbiota. Frontiers in Microbiomes. 2023, 2: 1194516. Distributed under Open Access license CC BY 4.0, without modification.
Click the button below to contact us or submit your feedback about this product.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
Copyright © 2024 Creative Biolabs. All Rights Reserved.